Literature DB >> 23206650

ACR Appropriateness Criteria radiologic management of hepatic malignancy.

Brian E Kouri1, Brian S Funaki, Charles E Ray, Ghassan K Abou-Alfa, Charles T Burke, Michael D Darcy, Nicholas Fidelman, Frederick L Greene, Stephen A Harrison, Thomas B Kinney, Jon K Kostelic, Jonathan M Lorenz, Ajit V Nair, Albert A Nemcek, Charles A Owens, Wael E A Saad, George Vatakencherry.   

Abstract

Management of hepatic malignancy is a challenging clinical problem involving several different medical and surgical disciplines. Because of the wide variety of potential therapies, treatment protocols for various malignancies continue to evolve. Consequently, development of appropriate therapeutic algorithms necessitates consideration of medical options, such as systemic chemotherapy; surgical options, such as resection or transplantation; and locoregional therapies, such as thermal ablation and transarterial embolization. The authors discuss treatment strategies for the 3 most common subtypes of hepatic malignancy treated with locoregional therapies: hepatocellular carcinoma, neuroendocrine metastases, and colorectal metastases. The ACR Appropriateness Criteria(®) are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Copyright © 2012 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23206650     DOI: 10.1016/j.jacr.2012.09.002

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  2 in total

1.  Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells.

Authors:  Lin-Feng Xu; Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Yu-Dan Wu
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

Review 2.  Assessment of Treatment Response Following Yttrium-90 Transarterial Radioembolization of Liver Malignancies.

Authors:  Charles S Adcock; Edward Florez; Kevin A Zand; Akash Patel; Candace M Howard; Ali Fatemi
Journal:  Cureus       Date:  2018-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.